



Vol. 46, No. 1
SPRING 2012

The Bovine **PRACTITIONER**

THE OFFICIAL PUBLICATION OF THE
AMERICAN ASSOCIATION OF BOVINE PRACTITIONERS

Property of
Medical Sciences Library
Texas A&M University



© Copyright American Association of Bovine Practitioners; open access distribution.

45th ANNUAL CONFERENCE

American Association of Bovine Practitioners
Montreal, Canada
September 20-22, 2012



DISCOVER AN EXTRA CALF IN EVERY BOTTLE

Vaccinating with Vision® 7 results in 14 pounds more weaning weight per calf than Ultrabac® 7 — You get an extra calf in every 50-dose bottle.

Blackleg vaccination stress can decrease performance, but Vision® minimizes the negative impact of vaccination.

The proof is in the pounds. Studies show:

- Less stress in calves vaccinated with Vision 2mL compared to 5mL blackleg vaccines results in a weaning weight advantage from 9 to 18 pounds
- Vision 7 2mL resulted in a 14-pound weaning weight advantage when compared to Ultrabac 7 5mL* — that's an extra calf in every 50-dose bottle

Take the stress out of blackleg protection. Consult your Merck Animal Health representative on switching to Vision vaccine today.

*Intervet Technical Reference 93-9: Weaning Weight Comparison of Vision 7 and Ultrabac 7 in a Wyoming Beef Herd

Vision®





The Bovine PRACTITIONER

EDITOR:
ROBERT A. SMITH, DVM
3404 Live Oak Lane
Stillwater, Oklahoma 74075
Tel: (405) 372-8666
Fax: (405) 743-8422

PUBLISHER:
VM PUBLISHING COMPANY
205 W. 7th Avenue, Suite 201G
Stillwater, Oklahoma 74074
Tel/Fax: (405) 533-1883
kellijo.vmpubco@gmail.com

OFFICERS

President **Brian Gerloff, DVM**
Marengo, Illinois

President-Elect **Nigel Cook, DVM**
Madison, Wisconsin

Vice President **Daniel L. Grooms, DVM**
Williamston, Michigan

Past President **Christine Navarre, DVM**
Baton Rouge, Louisiana

Executive Vice President **M. Gatz Riddell, Jr., DVM**
Auburn, Alabama

Treasurer **Brian Reed, DVM**
Lititz, Pennsylvania

Parliamentarian **Patty Scharko, DVM**
Columbia, South Carolina

BOARD OF DIRECTORS

Mark J. Thomas, DVM
Carthage, New York
1st District, 2014

Bob Cloninger, VMD
Centre Hall, Pennsylvania
2nd District, 2012

James A. Brett, DVM
Starkville, Mississippi
3rd District, 2013

Garold Koester, DVM
Cadillac, Michigan
4th District, 2014

Glen Johnson, DVM
Reedsburg, Wisconsin
5th District, 2012

Sarah Overby, DVM
Freeport, Minnesota
6th District, 2013

Rodney Chapman, DVM
Versailles, Missouri
7th District, 2014

Glenn Rogers, DVM
Aledo, Texas
8th District, 2012

David Rethorst, DVM
Hastings, Nebraska
9th District, 2013

Steve Smalley, VMD
Chandler, Arizona
10th District, 2014

Fred Muller, DVM
Sunnyside, Washington
11th District, 2012

Guy R. Boisclair, DVM
Victoriaville, Quebec, Canada
12th District, 2013

J. Egan Brockhoff, DVM
Canmore, Alberta, Canada
13th District, 2014

AVMA DELEGATE:

Mark Spire, DVM

Manhattan, Kansas

EXHIBITS CHAIRMAN:

Charlie Hatcher, DVM

College Grove, Tennessee

ADVERTISING AGENCY:

J. T. O'Brien & Assoc.

12118 Nieman Road

Overland Park, Kansas 66213

913-402-8383 Fax: 913-402-8384

THE BOVINE PRACTITIONER is published by The American Association of Bovine Practitioners, Inc., at **VM Publishing Co., 205 W. 7th, Suite 201G, Stillwater, OK 74074 (Telephone and Fax: 405-533-1883)**. Over 6000 copies are mailed to veterinarians engaged in cattle practice and allied institutions. Send new address (please include old address) to:

AABP, P.O. Box 3610, Auburn, AL 36831-3610

Tel: 1-800-269-2227; FAX 334-821-9532

e-mail: aabphq@aabp.org

http://www.aabp.org

THE BOVINE PRACTITIONER is the official publication of The American Association of Bovine Practitioners, published in the spring and summer annually. It also serves as a communication medium between bovine practitioner organizations around the world. All manuscripts and communications must be presented in English.

Copies of THE BOVINE PRACTITIONER are available to non-members for \$25.00 per copy for domestic destinations, or \$35.00 for international addresses. **Contact editor for details.**

Table of Contents

A review of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in dairy cattle <i>J. Pinto Ferreira, M. T. Correa, R. Lyman, K. L. Anderson</i>	1
Immunological response of dairy cattle housed at an Ontario animal exhibit to vaccination with <i>Escherichia coli</i> O157 Type III secreted proteins <i>Glenn G. Smith, Susan E. Goebel, Louis A. Guilbault, Louisa J. Zak, Xiaogang Li</i>	10
Developing a practice-based microbiological laboratory to guide mastitis treatment on dairy farms <i>James W. Bennett, Joanna L. Gardner</i>	18
Case report— <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> infection in three generations of beef cattle <i>Julia M. Smith, Robert H. Whitlock</i>	32
Trends in export of dairy Holstein heifers from the United States <i>Michaela A. Kristula, Billy I. Smith, Jon Garber, Mathew L. Stock</i>	36
A comparison of tilmicosin to gamithromycin for on-arrival treatment of bovine respiratory disease in feeder steers <i>Joyce Van Donkersgoed, John K. Merrill</i>	46
Case study: Effects of undifferentiated bovine respiratory disease on performance and marbling deposition in feedlot steers fed to a common yield grade endpoint <i>Daniel U. Thomson, Eric S. Moore, Brad J. White, Chris D. Reinhardt</i>	52
Evaluation of generic injectable ivermectin for control of nematodiasis in feedlot heifers <i>T. A. Yazwinski, C. A. Tucker, D. G. Miles, J. L. Reynolds, L. L. Jones, J. A. Hornsby, M. T. Smith, B. E. Martin</i>	60

Advertisers Index

Addison Biological Laboratory, Inc.	31
Arm & Hammer Animal Nutrition.....	59
Merck Animal Health	inside front cover, front of book, inside back cover
Norbrook Laboratories Limited.....	66
Novartis Animal Health	17
Pfizer Animal Health	back cover

*Cover photo courtesy of Deseret Cattle and Citrus, St. Cloud, Florida.
Additional photos courtesy of Dr. Bob Smith, Stillwater, Oklahoma*

*The abstracts were translated to French by Dr. Guy Beauchamp
and revised by Dr. Emile Bouchard.*

Notice to Readers

All statements, opinions and conclusions contained in articles in *The Bovine Practitioner* are those of the author(s), and are not necessarily those of the American Association of Bovine Practitioners (AABP) unless specifically approved by the AABP Board of Directors.



SEE IMPROVEMENT FROM BRD SYMPTOMS IN AS LITTLE AS 6 HOURS



See a Difference in One Dose

Broad-spectrum Resflor Gold[®] goes to work fast on BRD. It offers the dual activity of an antibiotic and a non-steroidal anti-inflammatory drug in one.

See for yourself with our 60-second video at www.resflorgold.com.

See your Merck Animal Health sales representative or animal health supplier for more information.

For subcutaneous use in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal. The effects of florfenicol and flunixin on bovine reproductive performance, pregnancy, and lactation have not been determined. When administered according to the label directions, RESFLOR GOLD may induce a transient local reaction in the subcutaneous and underlying muscle tissue. Full product information on the following page.

Copyright © 2012 Intervet, Inc., a subsidiary of Merck and Co, Inc. Intervet Inc. d/b/a Merck Animal Health 556 Morris Avenue, Summit, NJ 07901. All rights reserved. RES-143

PRODUCT INFORMATION
NADA 141-299, Approved by FDA.



(Florfenicol and Flunixin Meglumine)
Antimicrobial/Non-Steroidal Anti-Inflammatory Drug

For subcutaneous use in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

BRIEF SUMMARY: For full prescribing information, see package insert.

INDICATION: RESFLOR GOLD® is indicated for treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni*, and *Mycoplasma bovis*, and control of BRD-associated pyrexia in beef and non-lactating dairy cattle.

CONTRAINDICATIONS: Do not use in animals that have shown hypersensitivity to florfenicol or flunixin.

WARNINGS: NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. This product contains material that can be irritating to skin and eyes. Avoid direct contact with skin, eyes, and clothing. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. Consult a physician if irritation persists. Accidental injection of this product may cause local irritation. Consult a physician immediately. The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information.

For customer service or to obtain a copy of the MSDS, call 1-800-211-3573. For technical assistance or to report suspected adverse reactions, call 1-800-219-9286.

Not for use in animals intended for breeding purposes. The effects of florfenicol on bovine reproductive performance, pregnancy, and lactation have not been determined. Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy. NSAIDs are known to have potential effects on both parturition and the estrous cycle. There may be a delay in the onset of estrus if flunixin is administered during the prostaglandin phase of the estrous cycle. The effects of flunixin on imminent parturition have not been evaluated in a controlled study. NSAIDs are known to have the potential to delay parturition through a tocolytic effect.

RESFLOR GOLD®, when administered as directed, may induce a transient reaction at the site of injection and underlying tissues that may result in trim loss of edible tissue at slaughter.

RESIDUE WARNINGS: Animals intended for human consumption must not be slaughtered within 38 days of treatment. Do not use in female dairy cattle 20 months of age or older. Use of florfenicol in this class of cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

ADVERSE REACTIONS: Transient inappetence, diarrhea, decreased water consumption, and injection site swelling have been associated with the use of florfenicol in cattle. In addition, anaphylaxis and collapse have been reported post-approval with the use of another formulation of florfenicol in cattle.

In cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use of flunixin meglumine.

Made in Germany
Intervet Inc. Roseland, NJ 07068
©2009, Intervet Inc. All Rights Reserved.
Mav 2009

US 3448 IV